Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06934863
Recruiting Observational

Rate of Malignant Transformation and Clinical Characteristics Among an Oral Lichen Planus Cohort: a Retrospective Center Experience

NCT06934863 · tracked via the Priya Life Science Italy tracker
Sponsor
Catholic University of the Sacred Heart
Phase
Observational
Started
2024-01-31
Last updated
2026-05-14

Condition(s) studied

Oral Lichen PlanusOral CarcinomaOral Carcinoma in Situ

Study summary

The main objective of this paper will be to evaluate the rate of malignant transformation among a cohort of patients affected by oral lichen planus with long-term follow-up. Secondary aims will be to study and describe the characteristics of these patients to identify potential risk factors for malignant transformation, and to evaluate the therapeutic effects and features to OLP drgus.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Clinical-histological diagnosis of Oral lichen planus * Patients who gave consensus to personal data treatment * Minimum 6 months follow-up Exclusion Criteria: * Patients who did not give consensus to personal data treatment * Oral lichenoid lesions * Patients with anamnesis of hematopoietic stem cells transplant * Patients with a OSCC at the first histological examination (i.e., namely: also OSCC patients with a OLP background were excluded)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Catholic University of the Sacred Heart Roma Italy Recruiting

More Catholic University of the Sacred Heart trials in Italy

Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery Starting soon
Showers and Stress Recruiting
Evaluation of Polygenic Risk Score for Epithelial OVarian cancEr Risk Prediction: the PROVE Study Recruiting
MobACT: An Internet-Based Intervention for Chronic Pain Patients Recruiting
Multi-omics Dissection of Gut Microbiome Engraftment During FMT Starting soon

Other trials for the same condition

Mucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen Planus Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06934863 on ClinicalTrials.gov ↗ ← All trials in Italy